Claims for Patent: 8,865,937

Summary for Patent: 8,865,937

Title:	Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
Abstract:	The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.
Inventor(s):	Dedhiya; Mahendra G. (Pomona, NY), Surana; Rahul (Commack, NY)
Assignee:
Application Number:	12/941,293
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,865,937
Patent Claims:	1. A crystalline form of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide hydrochloride having an X-ray powder diffraction pattern comprising characteristic peaks at 12.0.+-.0.2 degrees 2.theta., 20.1.+-.0.2 degrees 2.theta. and 22.5.+-.0.2 degrees 2.theta.. 2. The crystalline form of claim 1, wherein the X-ray powder diffraction pattern further comprises a characteristic peak at 29.2.+-.0.2 degrees 2.theta.. 3. The crystalline form of claim 1, having a melting endotherm at about 200.degree. C. as determined by differential scanning calorimetry. 4. The crystalline form of claim 1, having a Raman spectrum that comprises characteristic peaks at about 695, about 735 and about 1435 cm.sup.-1. 5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an active ingredient that comprises a crystalline form of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide hydrochloride having an X-ray powder diffraction pattern comprising characteristic peaks at 12.0.+-.0.2 degrees 2.theta., 20.1.+-.0.2 degrees 2.theta. and 22.5.+-.0.2 degrees 2.theta.. 6. The pharmaceutical composition of claim 5, wherein the X-ray powder diffraction pattern further comprises a characteristic peak at 29.2.+-.0.2 degrees 2.theta.. 7. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is a sustained release tablet or capsule that comprises about 20 mg of the active ingredient. 8. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is a sustained release tablet or capsule that comprises about 40 mg of the active ingredient. 9. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is a sustained release tablet or capsule that comprises about 80 mg of the active ingredient. 10. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is a sustained release tablet or capsule that comprises about 120 mg of the active ingredient. 11. The pharmaceutical composition of claim 5, wherein the active ingredient comprises greater than about 20 wt. % of the crystalline form. 12. The pharmaceutical composition of claim 5, wherein the active ingredient comprises greater than about 60 wt. % of the crystalline form. 13. The pharmaceutical composition of claim 5, wherein the active ingredient comprises greater than about 90 wt. % of the crystalline form. 14. A process for preparing a crystalline form of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide hydrochloride, wherein the process comprises dissolving (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide hydrochloride in a solvent comprising substantially pure ethanol and precipitating the crystalline form. 15. The process of claim 14, wherein the solvent comprises greater than 96% by weight of ethanol. 16. The process of claim 14, wherein the solvent comprises greater than 98% by weight of ethanol. 17. A crystalline form of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide hydrochloride prepared by the process of any of claims 15-16.